Why Lupin’s Glyree 1 mg quietly matters in everyday diabetes care

Glyree 1 mg from Lupin is one of those diabetes tablets that rarely grabs headlines but sits reliably in medicine boxes across India. What exactly does this small white pill offer, where are its limits, and who is it really for?

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-21, 22:11. Details in the imprint.

Glyree 1 mg from Lupin is the kind of diabetes pill you do not notice until a parent or grandparent takes it every morning with tea. The tablet is tiny, chalky to the touch, goes down with a sip of water, and promises more stable blood sugar through the day.

What Glyree 1 mg actually is

Glyree 1 mg is a prescription oral antidiabetic tablet containing the sulfonylurea glimepiride, typically positioned for adults with type 2 diabetes whose blood sugar is not adequately controlled by diet and exercise alone.

Lupin’s product information and Indian pharmacy listings describe Glyree 1 mg as a once-daily tablet, usually taken with breakfast or the first main meal to lower fasting and post-meal glucose by increasing insulin release from the pancreas.

How it works in everyday use

In practice, patients are often started on Glyree 1 mg as an initial low dose, which physicians can gradually titrate upwards depending on blood glucose response and tolerability, a pattern reflected in glimepiride use globally.

Because Glyree stimulates insulin secretion, users are advised to eat regular meals, carry a small snack, and watch for early signs of hypoglycaemia such as sweating, tremor, or sudden hunger, especially when doses are increased or meals are delayed.

Strengths that make it a longseller

The appeal of Glyree 1 mg in India is its combination of a familiar mechanism, once-daily dosing, and aggressive generic pricing, which makes sustained treatment financially tolerable for middle-income families managing long-term diabetes.

In many prescriptions, Glyree is combined with metformin in the same regimen, a pairing that endocrinology guidelines view as consistent with long-standing practice for patients who need more than lifestyle and metformin alone to reach targets.

Where the limits show up

The flip side of this older class is risk: sulfonylureas like glimepiride are known for hypoglycaemia and weight gain, so Glyree 1 mg is generally unsuitable for people with frequent low sugars or very irregular eating patterns.

International diabetes guidelines in recent years have shifted toward SGLT2 inhibitors and GLP-1 receptor agonists for many high-risk patients, which means a tablet like Glyree is now more of a cost-sensitive workhorse than a cutting-edge therapy.

Pricing and availability in India

Indian online pharmacy listings show Glyree 1 mg in strips of 10 tablets, typically priced in a low double-digit rupee range per strip, with further discounts through large e-pharmacies that ship pan-India.

Glyree 1 mg is not a product for the German OTC shelf but a prescription medicine focused on the Indian and some emerging markets, where Lupin has a strong presence in chronic therapies.

Why it still matters for Lupin

For Lupin Ltd, mature diabetes brands such as Glyree help provide recurring revenue alongside newer complex generics and specialty launches highlighted in the company’s recent investor updates.

Shares of Lupin Ltd (INE326A01037) trade on the National Stock Exchange of India and BSE in Mumbai, anchoring one of India’s better-known pharmaceutical stories for long-term investors.

Key facts on Glyree 1 mg

• Product: Glyree 1 mg
• Manufacturer: Lupin Ltd.
• Category: Classic/Longseller prescription medicine
• Launch: Marketed in India for several years as a glimepiride tablet (exact first launch year not publicly specified)
• RRP / Price: Typically low double-digit Indian rupees per strip of 10 tablets, with discounts via Indian e-pharmacies
• Availability: Prescription-only in India and selected emerging markets via local pharmacies and online pharmacy platforms
• Target group: Adults with type 2 diabetes requiring an oral sulfonylurea alongside diet and exercise
• Highlight / USP: Established once-daily glimepiride tablet positioned as an affordable, widely available option in India’s large diabetes market

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.